JorgeEnriqueMachado-‐Alba
86
4. Greenhalgh J, Bagust A, Boland A, Blundell M, Oyee J, Beale S, et al. Rituximab for the First-‐
Line Maintenance Treatment of Follicular Non-‐Hodgkin's Lymphoma : A NICE Single
TechnologyAppraisal. Pharmacoeconomics
31
(5), 403-‐13(2013).
5. Niyazi M, Maihoefer C, Krause M, Rödel C, Budach W, Belka C. Radiotherapy and "new"
drugs-‐newsideeffects?RadiatOncol
6
, 177(2011).
6. Yan L. Molecular targeted agents-‐-‐where we are and where we are going. Chin J Cancer
32
(5), 225-‐32(2013).
7. American Pharmacists Associaton. Drug Information Handbook. 21st Edition. Lexicomp
2012
8. Tak P, Kalden J. Advances in rheumatology: new targeted therapeutics. Arthritis Res Ther
13
(Suppl 1), S5(2011).
9. Dyer MJ. Safety and efficacy of ofatumumab in patients with fludarabine and alemtuzumab
refractorychronic lymphocytic leukaemia. TherAdvHematol
3
(4), 199-‐207(2012).
10.WuM, Akinleye A, Zhu X. Novel agents for chronic lymphocytic leukemia. J Hematol Oncol
6
, 36(2013).
11. Warner JL, Arnason JE. Alemtuzumab use in relapsed and refractory chronic lymphocytic
leukemia: a history and discussion of future rational use. Ther Adv Hematol
3
(6), 375-‐89
(2012).
12. Kousin-‐Ezewu O, Coles A. Alemtuzumab inmultiple sclerosis: latest evidence and clinical
prospects. TherAdvChronicDis
4
(3), 97-‐103(2013).
13. FeldmannG, Brossart P, ZipfelM, vonLilienfeld-‐ToalM.Mixed response to ipilimumab ina
melanoma patient with brain metastases: case report and review of the literature. Case
RepOncol
6
(1), 229-‐35(2013).
14. Wolchok JD, Kluger H, CallahanMK, PostowMA, Rizvi NA, Lesokhin AM, et al. Nivolumab
plus Ipilimumab inAdvancedMelanoma. NEngl JMed
369
(2), 122-‐33(2013).
15. Chiche L, Jourde N, Thomas G, BardinN, Bornet C, Darque A, et al. New treatment options
for lupus -‐ a focusonbelimumab. TherClinRiskManag
8
, 33-‐43(2012).
16. Kim SS, Kirou KA, Erkan D. Belimumab in systemic lupus erythematosus: an update for
clinicians. TherAdvChronicDis
3
(1), 11-‐23(2012).
17. HamidO, Robert C, DaudA, Hodi FS, HwuWJ, KeffordR, et al. Safety andTumorResponses
withLambrolizumab (Anti-‐PD-‐1) inMelanoma. NEngl JMed
369
(2), 134-‐44(2013).
18. Beck A, Reichert JM. Marketing approval of mogamulizumab: a triumph for glyco-‐
engineering.MAbs
4
(4), 419-‐25(2012).
19. Tobinai K, Takahashi T, Akinaga S. Targeting chemokine receptor CCR4 in adult T-‐cell
leukemia-‐lymphoma and other T-‐cell lymphomas. Curr Hematol Malig Rep
7
(3), 235-‐40
(2012).
20. Cooper KL, Madan J,Whyte S, StevensonMD, Akehurst RL. Granulocyte colony-‐stimulating
factors for febrile neutropenia prophylaxis following chemotherapy: systematic review
andmeta-‐analysis. BMCCancer
11
, 404(2011).
21. Barosi G, Bosi A, AbbracchioMP, Danesi R, Genazzani A, Corradini P, et al. Keyconcepts and
critical issues on epoetin and filgrastim biosimilars. A position paper from the Italian
Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for
BoneMarrowTransplantation. Haematologica
96
(7), 937-‐42(2011).
22. Agarwal R, Abidi MH. Successful autologous stem cell collection with filgrastim and
plerixafor after long-‐term lenalidomide therapy formultiplemyeloma. Hematol Rep
4
(4),
e26(2012).
23. Arora S, Bhargava A, Jasnosz K, Clark B. Relapsing acute kidney injury associated with
pegfilgrastim. CaseRepNephrolUrol
2
(2), 165-‐71(2012).
24. Cesaro S, Nesi F, Tridello G, Abate M, Panizzolo IS, Balter R, et al. A randomized, non-‐
inferiority study comparing efficacy and safety of a single dose of pegfilgrastim versus
daily filgrastim in pediatric patients after autologous peripheral blood stem cell
transplant. PLoSOne
8
(1), e53252(2013).
25. JawadM, YuN, SeedhouseC, TandonK, RussellNH, PallisM. Targetingof CD34+CD38-‐ cells
using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in
AcuteMyeloidLeukaemia. BMCCancer
12
, 431(2012).
26. Zinzani PL, Viviani S, AnastasiaA, VitoloU, Luminari S, ZajaF, et al. Brentuximabvedotin in
relapsed/refractoryHodgkin's lymphoma: Italian experience and results of the use in the
dailyclinicoutsideclinical trials. Haematologica
98
(8), 1232-‐6(2013).